This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



DosingMechanism of ActionSafety & TolerabilityEfficacy & Clinical DataSupport & ResourcesMaterialsVideosPrescribing Information
DosingINLYTA® (axitinib) has a flexible dosing regimen and short half-life1

The recommended starting dose of INLYTA® is 5 mg twice daily, taken orally, approximately 12 hours apart, with or without food.1 INLYTA® is available in 1 mg and 5 mg dose strengths to help dose adjustment.1

Flexible dosing regimen

Dose increase or reduction is recommended based on individual safety and tolerability.

The dose of INLYTA® can be increased or decreased in the absence or presence of adverse reactions. If a patient tolerates the recommended starting dose of 5 mg twice daily with no adverse reactions greater than grade 2 for 2 consecutive weeks, you can step up to 7 mg twice daily, unless their blood pressure is greater than 150/90 mmHg or they’re taking antihypertensive treatment.1 The same criteria can then be applied to further increase their dose of INLYTA® to a maximum of 10 mg twice daily.1 Conversely, if adverse reactions develop, the dose of INLYTA® can be reduced to 3 mg twice daily and then to 2 mg twice daily if needed.1 Managing some adverse reactions may need temporary or permanent discontinuation and/or dose reduction of Inlyta® therapy.1

Watch a short video on INLYTA® dosing LoadingShort half-life

A short half-life could potentially lead to a relatively quick resolution of some adverse reactions following temporary treatment discontinuation.1–3 

The half-life of INLYTA® is between 2.5 and 6.1 hours. Based on the short half-life of Inlyta, steady state is expected within 2 to 3 days of the initial dose.1

Once any adverse reactions subside, treatment with INLYTA® can be restarted, if necessary at a reduced dose.1,3 INLYTA® should be permanently discontinued if adverse events do not resolve.1

The flexible dosing regimen and short half-life of INLYTA® could help you manage some adverse reactions1–3 
ReferencesINLYTA® Summary of Product Characteristics.Rini BI, et al. Clin Genitourin Cancer 2021. DOI: clgc.2021.03.019.Schmidinger M, et al. Future Oncol 2018;14:861–875.
Resources Explore Loading

Legal Category: S1A
Further information is available upon request

PP-INL-IRL-0132 December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.